Literature DB >> 29472379

DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome.

Dimitra Argyro Vassiliadi, Stylianos Tsagarakis.   

Abstract

Desmopressin is a vasopressin analogue selective for type 2 vasopressin receptors that mediate renal water retention. In contrast to the native hormone arginine vasopressin, a well-known ACTH secretagogue, desmopressin, exerts minimal or no activity on ACTH excretion. However, in a substantial proportion of patients with ACTH-dependent Cushing's syndrome (CS), desmopressin elicits an ACTH and cortisol response, which contrasts with the minimal responses obtained in healthy subjects. The mechanism underlying this paradoxical response involves upregulation of vasopressin type 3 and/or the aberrant expression of type 2 receptors by neoplastic ACTH-producing cells. This makes desmopressin administration a suitable test enabling the distinction between neoplastic from functional (formerly termed 'pseudo-Cushing syndrome') ACTH-dependent cortisol excess. Several studies have now established an adjunctive role of desmopressin in the initial diagnostic workup of CS. Despite some early data indicating that this test may also have a role in distinguishing between Cushing's disease (CD) and ectopic ACTH secretion, subsequent studies failed to confirm this observation. The ability of the paradoxical response to desmopressin to depict the presence of neoplastic ACTH-secreting cells was also exploited in the follow-up of patients with CD undergoing surgery. Loss of the desmopressin response, performed in the early postoperative period, was a good predictor for a favorable long-term outcome. Moreover, during follow-up, reappearance of desmopressin paradoxical response was an early indicator for recurrence. In conclusion, the desmopressin test is a valid tool in both the diagnosis and follow-up of patients with CD and should be more widely applied in the workup of these patients.
© 2018 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29472379     DOI: 10.1530/EJE-18-0007

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  13 in total

1.  Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.

Authors:  Cédric Fontaine-Sylvestre; Laurent Létourneau-Guillon; Robert A Moumdjian; France Berthelet; André Lacroix
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

Review 2.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

3.  How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing).

Authors:  Carla Scaroni; Alessandro Mondin; Filippo Ceccato
Journal:  Pituitary       Date:  2022-05-26       Impact factor: 3.599

Review 4.  Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing's Syndrome.

Authors:  Lynnette K Nieman
Journal:  Endocr Rev       Date:  2022-09-26       Impact factor: 25.261

5.  Copeptin Levels Before and After Transsphenoidal Surgery for Cushing Disease: A Potential Early Marker of Remission.

Authors:  Chelsi Flippo; Christina Tatsi; Ninet Sinaii; Maria De La Luz Sierra; Elena Belyavskaya; Charalampos Lyssikatos; Meg Keil; Elias Spanakis; Constantine A Stratakis
Journal:  J Endocr Soc       Date:  2022-04-06

Review 6.  Cyclic Cushing's Syndrome - A Diagnostic Challenge.

Authors:  Renata Świątkowska-Stodulska; Agata Berlińska; Katarzyna Stefańska; Przemysław Kłosowski; Krzysztof Sworczak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

Review 7.  Treatment challenges in pediatric Cushing's disease: Review of the literature with particular emphasis on predictive factors for the disease recurrence.

Authors:  Katarzyna Pasternak-Pietrzak; Elżbieta Moszczyńska; Mieczysław Szalecki
Journal:  Endocrine       Date:  2019-11-07       Impact factor: 3.633

8.  Is it Time for a New Approach to the Differential Diagnosis of ACTH-Dependent Cushing Syndrome?

Authors:  Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

Review 9.  Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge.

Authors:  José Miguel Hinojosa-Amaya; Elena V Varlamov; Shirley McCartney; Maria Fleseriu
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-08       Impact factor: 5.555

10.  Case Report: Three Rare Cases of Ectopic ACTH Syndrome Caused by Adrenal Medullary Hyperplasia.

Authors:  Yu Cheng; Jie Li; Jingtao Dou; Jianming Ba; Jin Du; Saichun Zhang; Yiming Mu; Zhaohui Lv; Weijun Gu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-01       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.